MAGNETOM Sola; MAGNETOM Altea

The MAGNETOM Sola and Altea systems, updated with syngo MR XA61A software, aim to advance diagnostic magnetic resonance imaging by delivering superior image quality, novel clinical applications, and enhanced workflow efficiency. This enhancement is realized through upgraded hardware components and innovative software features, notably AI-powered 'Deep Resolve Boost' for accelerated and improved image reconstruction, specialized applications like 'myExam Implant Suite,' and 'Low SAR protocols,' all validated via comprehensive non-clinical testing and supported by scientific literature.

The MAGNETOM Sola and MAGNETOM Altea systems, equipped with the syngo MR XA61A software, are magnetic resonance diagnostic devices designed to generate a comprehensive range of images (including transverse, sagittal, coronal, oblique cross-sectional, and spectroscopic) and spectra. These outputs visualize the internal structures and functions of the head, body, or extremities, serving as a critical tool for physicians in diagnosis; the systems also support imaging during interventional procedures when used with MR-compatible equipment, and contrast agents may be employed depending on the region of interest. These updated systems feature new and modified hardware, such as upgraded host computers (syngo MR Acquisition Workplace and syngo MR Workplace) and, for the MAGNETOM Sola, a new MaRS (Measurement and Reconstruction System) computer, alongside an enhanced myExam 3D Camera. Significant software advancements include new applications like GRE_PC, Physio logging, myExam Implant Suite, AI-driven 'Deep Resolve Boost' for HASTE and EPI Diffusion, and 'Complex Averaging.' Modified features like the OpenRecon Framework and 'Low SAR Protocols' aim to improve reconstruction and reduce Specific Absorption Rate for certain examinations. Non-clinical testing, including software verification, image quality assessments using sample clinical images, and validation of AI features (trained on extensive datasets using metrics like PSNR and SSIM), confirmed the intended performance and safety profile, with further support from clinical publications for features like Deep Resolve Boost, GRE_PC, and Complex Averaging.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does 'Deep Resolve Boost' quantitatively improve specific image quality metrics (e.g., SNR, CNR, spatial resolution) across different anatomical regions compared to the previous syngo MR XA51A software?; What is the measurable impact of the 'Low SAR Protocols' on examination times and image quality for the specified knee, spine, heart, and brain scans, particularly in temperature-sensitive patients?; Can the 'myExam Implant Suite' automatically adjust scan parameters based on identified implant types, and what range of implants does it effectively manage for artifact reduction?; How do the hardware modifications to the host computers and the MaRS system (for MAGNETOM Sola) translate into tangible benefits in processing speed for complex sequences like EPI Diffusion with Deep Resolve Boost?; Beyond the listed publications, what evidence supports the clinical utility and diagnostic equivalence of images generated with 'Complex Averaging' and 'GRE_PC' compared to established sequences?